Rapid News & Updates
“Imaging and Dosimetry for Alpha-Emitter RPT – Making the Impossible Routine,” presented by renowned experts George Sgouros and Eric Frey.
During this webinar, Drs. George Sgouros and Eric Frey will discuss how to implement imaging and dosimetry-driven treatment for alpha-emitter RPT (αRPT). They will highlight what is currently feasible and discuss emerging solutions for what remains challenging in αRPT. Quantitative, SPECT imaging and dosimetry of αRPT are complex but achievable. Using approaches that implement forward projection models with a multiple energy range (MER) method and appropriately defined and validated energy windows, imaging methods can measure the pharmacokinetics (PK) of the parent and alpha-emitting daughter radionuclides such as 213Bi in the case of 225Ac-labeled agents. Advances in imaging technologies such as CZT-based SPECT have the potential to make quantitative imaging more widely available, potentially without the need for sophisticated reconstruction algorithms.
This webinar promises to be an invaluable opportunity to learn from one of the foremost authorities in the field and gain a deeper understanding of the latest advancements in α-emitter therapies.
Â
Rapid’s, FDA-cleared dosimetry software, 3D-RD-S, Receives CE Mark Approval, Expanding Global Access to Cutting-Edge Radiopharmaceutical Dosimetry Software
Baltimore, Maryland, – Rapid®, a trailblazer in quantitative imaging and dosimetry solutions, is proud to announce the approval of the CE mark for its dosimetry
Radiopharmaceutical Imaging and Dosimetry (Rapid®) receives FDA clearance for its first 3D-RD™ product: 3D-RD-S
Baltimore, Maryland – Rapid is pleased to announce that it has received FDA 510(k) market clearance for its first software product: 3D-RD-S, the first web-browser based application that implements the MIRD Schema to perform radiopharmaceutical dosimetry calculations.
Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.
Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.
Rapid receives a $299k/$2.0M NCI Fast track Phase I/II Contract, Targeted Radionuclide Therapy of Metastatic Liver Cancer: Patient Specific Optimization.
Rapid receives a $299k/$2.0M NCI Fast track Phase I/II Contract, Targeted Radionuclide Therapy of Metastatic Liver Cancer: Patient Specific Optimization.
Rapid’s, FDA-cleared dosimetry software, 3D-RD-S, Receives CE Mark Approval, Expanding Global Access to Cutting-Edge Radiopharmaceutical Dosimetry Software
Baltimore, Maryland, – Rapid®, a trailblazer in quantitative imaging and dosimetry solutions, is proud to announce the approval of the CE mark for its dosimetry
Radiopharmaceutical Imaging and Dosimetry (Rapid®) receives FDA clearance for its first 3D-RD™ product: 3D-RD-S
Baltimore, Maryland – Rapid is pleased to announce that it has received FDA 510(k) market clearance for its first software product: 3D-RD-S, the first web-browser based application that implements the MIRD Schema to perform radiopharmaceutical dosimetry calculations.
Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.
Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.
Precision RPT is enabled by Rapid absorbed-dose calculations software
Service Number One
Absorbed-dose calculations accompanied by error bars improve confidence in precision
Service Number Two
Service Number Three
Absorbed-dose calculations can accomade alfa and beta emmiter RPT
Service Number Four
Uniting External Beam Radiation Therapy (XRT) and Radiopharmaceutical Therapy (RPT)
Service Number Five
SPECT/CT or PET/CT images of RPT distribuition used to estimate the spatial distribution of absorbed dose